Blinatumomab bridges the gap between leukemia and immunity

DOI: 10.1080/2162402X.2017.1358335

Keywords: acute lymphoblastic leukemia, bispecific T-cell engager, CD4+CD25+FOXP3+ regulatory T cell, CD19, chimeric antigen receptor, immune checkpoint blockers

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text